Search
-
Jpm Gsk Transcript 11 Jan 2022
Media
https://www.gsk.com/media/7963/jpm-gsk-transcript-11-jan-2022.pdf
First published: 01 June 2022
-
Investor Information 2024
Media
https://www.gsk.com/media/11857/investor-information-2024.pdf
First published: 27 February 2025
-
Annual Report 2024
Media
https://www.gsk.com/media/11850/annual-report-2024.pdf
First published: 27 February 2025
-
FY 2024 results transcript
Media
https://www.gsk.com/media/11782/fy-2024-results-transcript.pdf
First published: 05 February 2025
-
20 F 2020
Media
https://www.gsk.com/media/7971/20-f-2020.pdf
First published: 01 June 2022
-
2024 Annual Report on Form 20-F
Media
https://www.gsk.com/media/11872/2024-annual-report-on-form-20-f.pdf
First published: 03 March 2025
-
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1
Media
ViiV Healthcare present their three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-dolutegravir-plus-lamivudine-three-year-data-confirming-long-term-viral-suppression/
First published: 05 October 2020
-
ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021
Media
ViiV Healthcare announce the presentation of 13 abstracts from its portfolio of pipeline prevention options.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-key-data-that-provides-further-support-for-the-use-of-2-drug-regimens/
First published: 22 September 2021
-
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
Media
Other key data to be presented include new HIV prevention findings for long-acting cabotegravir and predictors of response to N6LS
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-first-head-to-head-data-for-long-acting-hiv-treatment-cabenuva-against-daily-oral-biktarvy-at-croi-2023/
First published: 14 February 2023
-
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
Media
ViiV Healthcare to present new long-term findings at CROI 2022
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-long-term-findings-from-its-innovative-2-drug-and-long-acting-hiv-medicines-portfolio-at-croi-2022/
First published: 07 February 2022
